Crossmark

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Crossref DOI link: https://doi.org/10.1007/s00125-020-05317-y

Published Online: 2020-11-04

Published Print: 2021-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Keymeulen, Bart

van Maurik, André

Inman, Dave https://orcid.org/0000-0001-5820-4688
Oliveira, João https://orcid.org/0000-0001-5970-8992
McLaughlin, Rene

Gittelman, Rachel M.

Roep, Bart O. https://orcid.org/0000-0002-3110-7391
Gillard, Pieter https://orcid.org/0000-0001-9111-4561
Hilbrands, Robert https://orcid.org/0000-0003-0228-699X
Gorus, Frans https://orcid.org/0000-0002-9007-6177
Mathieu, Chantal https://orcid.org/0000-0002-4055-5233
Van de Velde, Ursule

Wisniacki, Nicolas https://orcid.org/0000-0002-1681-9948
Napolitano, Antonella
Funding

Funding for this research was provided by:

GlaxoSmithKline
License Information

Text and Data Mining valid from 2020-11-04

Version of Record valid from 2020-11-04
More Information

Article History

Received: 14 May 2020

Accepted: 9 September 2020

First Online: 4 November 2020